Home » Posts tagged 'Shifa Pharmed'
Tag Archives: Shifa Pharmed
SEARCH THIS BLOG
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREBlog Stats
- 4,798,541 hits
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- December 2025 (20)
- November 2025 (31)
- October 2025 (22)
- September 2025 (24)
- August 2025 (27)
- July 2025 (25)
- June 2025 (23)
- May 2025 (34)
- April 2025 (32)
- March 2025 (4)
- October 2024 (4)
- September 2024 (17)
- May 2024 (4)
- April 2024 (2)
- February 2024 (8)
- January 2024 (1)
- December 2023 (3)
- November 2023 (2)
- October 2023 (1)
- September 2023 (1)
- August 2023 (4)
- July 2023 (1)
- April 2023 (1)
- March 2023 (1)
- January 2023 (5)
- December 2022 (3)
- November 2022 (3)
- October 2022 (9)
- September 2022 (9)
- August 2022 (7)
- July 2022 (2)
- June 2022 (7)
- May 2022 (5)
- April 2022 (7)
- March 2022 (7)
- February 2022 (12)
- January 2022 (15)
- December 2021 (26)
- November 2021 (17)
- October 2021 (21)
- September 2021 (21)
- August 2021 (19)
- July 2021 (13)
- June 2021 (30)
- May 2021 (7)
- April 2021 (9)
- March 2021 (25)
- February 2021 (10)
- January 2021 (17)
- December 2020 (21)
- November 2020 (5)
- October 2020 (5)
- September 2020 (12)
- August 2020 (3)
- July 2020 (5)
- June 2020 (1)
- May 2020 (1)
- April 2020 (1)
- March 2020 (19)
- February 2020 (9)
- January 2020 (12)
- December 2019 (4)
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (41)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (225)
- 2020 APPROVALS (48)
- accelerated approval (1)
- ACH 4471 (1)
- Acute Hepatic Porphyria (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANAESTHETIC (1)
- anaesthetics (4)
- analgesic (2)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (42)
- ANTI ACNE (2)
- ANTI DIABETES (4)
- ANTI DOPING (1)
- ANTI FUNGAL (6)
- ANTI HBV (1)
- ANTI INFLAMATORY (4)
- anti tubeculosis (1)
- antibacterial (10)
- Antibiotics (6)
- ANTIBODIES (54)
- ANTICONVULSANT (1)
- Antiemetic (2)
- antiglaucoma (1)
- Antihypertensives (3)
- antiinfluenza (2)
- antimalarials (12)
- Antineoplastic (29)
- antiobesity (1)
- Antispasmodic (1)
- ANTITUSSIVE (1)
- Antiulcerative (2)
- Antivirals (6)
- APPROVALS 2021 (86)
- APPROVALS 2022 (49)
- APPROVALS 2023 (35)
- approvals 2024 (55)
- APPROVALS 2025 (27)
- ARAB MEDICINE (5)
- Atopic dermatitis (1)
- Australia (1)
- AUSTRALIA 2021 (1)
- AWARD (13)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (4)
- BLOGS (28)
- Breakthrough Therapy Designation (69)
- canada (4)
- CANADA 2021 (1)
- cancer (170)
- cfda (6)
- CHINA 2011 (1)
- CHINA 2012 (1)
- CHINA 2018 (1)
- china 2019 (1)
- CHINA 2021 (5)
- CHINA 2022 (5)
- CHINA 2023 (4)
- CHINA 2024 (20)
- CHINA 2025 (1)
- china pipeline (37)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (7)
- Contrast agent (7)
- CORONAVIRUS (48)
- COVID-19 (46)
- CRL (1)
- CYSTIC FIBRIOSIS (2)
- Dengue (2)
- DEUTERATED (1)
- DIABETES (57)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- Duchenne muscular dystrophy (1)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (5)
- EU 2015 (6)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU 2019 (1)
- EU 2020 (5)
- EU 2021 (11)
- EU 2022 (4)
- EU 2023 (4)
- EU 2024 (1)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK (4)
- FAST TRACK FDA (78)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (7)
- FDA 2013 (6)
- FDA 2014 (53)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (53)
- FDA 2019 (44)
- FDA 2020 (34)
- fda 2021 (45)
- FDA 2022 (24)
- FDA 2023 (32)
- fda 2023, approvals 2023 (1)
- FDA 2024 (29)
- FDA 2025 (28)
- Featured product (1)
- female sexual dysfunction (1)
- FIBROMYGALIA (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Gastric Proton Pump Inhibitor (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (106)
- GENERICS (22)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- hepatitis C viral infections (1)
- Herbals (8)
- HOMEOPATHY (3)
- HORMONE (1)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- hypnotic (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND (1)
- IND 2017 (2)
- IND 2018 (3)
- IND 2021 (8)
- IND Filed (2)
- INDIA 2020 (5)
- INDIA 2022 (3)
- Insomnia (1)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2014 (1)
- JAPAN 2015 (2)
- JAPAN 2016 (1)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- japan 2020 (10)
- JAPAN 2021 (11)
- JAPAN 2022 (14)
- Japan marketing (34)
- Japan pipeline (38)
- Korea (3)
- korea 2012 (2)
- korea 2016 (1)
- korea 2019 (1)
- Lactams (1)
- MAA (3)
- Macrolides (2)
- Malaria (17)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- MIGRAINE (1)
- molybdenum cofactor deficiency (1)
- MONKEY POX (1)
- Monoclonal antibody (89)
- Nanotechnology (5)
- NCE (2)
- NDA (51)
- NDA JAPAN (3)
- neuropathic pain (1)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- non-Hodgkin's lymphoma (1)
- NUCLEOTIDES (1)
- obesity (3)
- OCCULAR (2)
- ocular hypertension (1)
- organic chemistry (12)
- osteoarthritis (2)
- PAIN (2)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (56)
- PFIZER (1)
- PHASE 1 (90)
- PHASE 3 (25)
- PHASE1 (145)
- Phase2 drugs (282)
- Phase3 drugs (306)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (14)
- Preclinical drugs (121)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (90)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (23)
- radio labelled (4)
- RADIOACTIVE AGENT (5)
- RADIOLABELLED (10)
- Rare disease (3)
- RARE PEDIATRIC DISEASE REVIEW (2)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (3)
- SCHLEROSING AGENT (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- Solid tumours (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TIVE (1)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,240)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (26)
- veterinary (7)
- virus (1)
- VITAMINS (3)
- x ray contrast agent (7)
Recent Posts
- Zemirciclib December 19, 2025
- Zelenirstat December 18, 2025
- Zavolosotine December 17, 2025
- Zamzetoclax December 16, 2025
- Vilzemetkib December 15, 2025
- Vicadrostat December 13, 2025
- Varegacestat December 13, 2025
- Tigozertinib December 12, 2025
- Tambiciclib December 11, 2025
- Talorasib December 11, 2025
- Talogreptide mesaroxetan December 10, 2025
- Suvadronabinol December 9, 2025
- Surzetoclax December 8, 2025
- Surlorian December 7, 2025
- Sumecigrel, Vicagrel December 6, 2025
ORGANIC SPECTROSCOPY

SUBSCRIBE
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by EmailDR ANTHONY MELVIN CRASTO Ph.D
DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards
Verified Services
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- December 2025 (20)
- November 2025 (31)
- October 2025 (22)
- September 2025 (24)
- August 2025 (27)
- July 2025 (25)
- June 2025 (23)
- May 2025 (34)
- April 2025 (32)
- March 2025 (4)
- October 2024 (4)
- September 2024 (17)
- May 2024 (4)
- April 2024 (2)
- February 2024 (8)
- January 2024 (1)
- December 2023 (3)
- November 2023 (2)
- October 2023 (1)
- September 2023 (1)
- August 2023 (4)
- July 2023 (1)
- April 2023 (1)
- March 2023 (1)
- January 2023 (5)
- December 2022 (3)
- November 2022 (3)
- October 2022 (9)
- September 2022 (9)
- August 2022 (7)
- July 2022 (2)
- June 2022 (7)
- May 2022 (5)
- April 2022 (7)
- March 2022 (7)
- February 2022 (12)
- January 2022 (15)
- December 2021 (26)
- November 2021 (17)
- October 2021 (21)
- September 2021 (21)
- August 2021 (19)
- July 2021 (13)
- June 2021 (30)
- May 2021 (7)
- April 2021 (9)
- March 2021 (25)
- February 2021 (10)
- January 2021 (17)
- December 2020 (21)
- November 2020 (5)
- October 2020 (5)
- September 2020 (12)
- August 2020 (3)
- July 2020 (5)
- June 2020 (1)
- May 2020 (1)
- April 2020 (1)
- March 2020 (19)
- February 2020 (9)
- January 2020 (12)
- December 2019 (4)
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (41)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (225)
- 2020 APPROVALS (48)
- accelerated approval (1)
- ACH 4471 (1)
- Acute Hepatic Porphyria (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANAESTHETIC (1)
- anaesthetics (4)
- analgesic (2)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (42)
- ANTI ACNE (2)
- ANTI DIABETES (4)
- ANTI DOPING (1)
- ANTI FUNGAL (6)
- ANTI HBV (1)
- ANTI INFLAMATORY (4)
- anti tubeculosis (1)
- antibacterial (10)
- Antibiotics (6)
- ANTIBODIES (54)
- ANTICONVULSANT (1)
- Antiemetic (2)
- antiglaucoma (1)
- Antihypertensives (3)
- antiinfluenza (2)
- antimalarials (12)
- Antineoplastic (29)
- antiobesity (1)
- Antispasmodic (1)
- ANTITUSSIVE (1)
- Antiulcerative (2)
- Antivirals (6)
- APPROVALS 2021 (86)
- APPROVALS 2022 (49)
- APPROVALS 2023 (35)
- approvals 2024 (55)
- APPROVALS 2025 (27)
- ARAB MEDICINE (5)
- Atopic dermatitis (1)
- Australia (1)
- AUSTRALIA 2021 (1)
- AWARD (13)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (4)
- BLOGS (28)
- Breakthrough Therapy Designation (69)
- canada (4)
- CANADA 2021 (1)
- cancer (170)
- cfda (6)
- CHINA 2011 (1)
- CHINA 2012 (1)
- CHINA 2018 (1)
- china 2019 (1)
- CHINA 2021 (5)
- CHINA 2022 (5)
- CHINA 2023 (4)
- CHINA 2024 (20)
- CHINA 2025 (1)
- china pipeline (37)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (7)
- Contrast agent (7)
- CORONAVIRUS (48)
- COVID-19 (46)
- CRL (1)
- CYSTIC FIBRIOSIS (2)
- Dengue (2)
- DEUTERATED (1)
- DIABETES (57)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- Duchenne muscular dystrophy (1)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (5)
- EU 2015 (6)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU 2019 (1)
- EU 2020 (5)
- EU 2021 (11)
- EU 2022 (4)
- EU 2023 (4)
- EU 2024 (1)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK (4)
- FAST TRACK FDA (78)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (7)
- FDA 2013 (6)
- FDA 2014 (53)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (53)
- FDA 2019 (44)
- FDA 2020 (34)
- fda 2021 (45)
- FDA 2022 (24)
- FDA 2023 (32)
- fda 2023, approvals 2023 (1)
- FDA 2024 (29)
- FDA 2025 (28)
- Featured product (1)
- female sexual dysfunction (1)
- FIBROMYGALIA (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Gastric Proton Pump Inhibitor (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (106)
- GENERICS (22)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- hepatitis C viral infections (1)
- Herbals (8)
- HOMEOPATHY (3)
- HORMONE (1)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- hypnotic (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND (1)
- IND 2017 (2)
- IND 2018 (3)
- IND 2021 (8)
- IND Filed (2)
- INDIA 2020 (5)
- INDIA 2022 (3)
- Insomnia (1)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2014 (1)
- JAPAN 2015 (2)
- JAPAN 2016 (1)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- japan 2020 (10)
- JAPAN 2021 (11)
- JAPAN 2022 (14)
- Japan marketing (34)
- Japan pipeline (38)
- Korea (3)
- korea 2012 (2)
- korea 2016 (1)
- korea 2019 (1)
- Lactams (1)
- MAA (3)
- Macrolides (2)
- Malaria (17)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- MIGRAINE (1)
- molybdenum cofactor deficiency (1)
- MONKEY POX (1)
- Monoclonal antibody (89)
- Nanotechnology (5)
- NCE (2)
- NDA (51)
- NDA JAPAN (3)
- neuropathic pain (1)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- non-Hodgkin's lymphoma (1)
- NUCLEOTIDES (1)
- obesity (3)
- OCCULAR (2)
- ocular hypertension (1)
- organic chemistry (12)
- osteoarthritis (2)
- PAIN (2)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (56)
- PFIZER (1)
- PHASE 1 (90)
- PHASE 3 (25)
- PHASE1 (145)
- Phase2 drugs (282)
- Phase3 drugs (306)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (14)
- Preclinical drugs (121)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (90)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (23)
- radio labelled (4)
- RADIOACTIVE AGENT (5)
- RADIOLABELLED (10)
- Rare disease (3)
- RARE PEDIATRIC DISEASE REVIEW (2)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (3)
- SCHLEROSING AGENT (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- Solid tumours (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TIVE (1)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,240)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (26)
- veterinary (7)
- virus (1)
- VITAMINS (3)
- x ray contrast agent (7)
Recent Comments
| shivkr2 on SPSR Excellence Award 2025 – S… | |
| Bonkasaurus on Infigratinib phosphate | |
| PALOVAROTENE | ORGAN… on Palovarotene | |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
SEARCH THIS BLOG
COVIran Barakat
June 21, 2021 9:47 am / 1 Comment on COVIran Barakat
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code | None |
| Legal status | |
| Legal status | Emergency use authorization: IRNFull and Emergency Authorizations: List of COVIran Barakat COVID-19 vaccine authorizations |
COVIran Barakat
COVIran Barakat, is an inactivated virus vaccine developed by Shifa Pharmed Industrial Co in Iran.[501
https://en.trend.az/iran/society/3439812.html
BAKU, Azerbaijan, Jun. 14 2021
By Elnur Baghishov – Trend:
An emergency license was issued for the use of the Iranian-made “CovIran Barakat” vaccine against the coronavirus yesterday on June 13, the Iranian Minister of Health and Medical Education Saeed Namaki said, Trend reports citing IRNA.
He made the remark in an event dedicated to the launch of a number of health and medical facilities in Iran’s Markazi Province today on June 14.
Namaki said that moreover, a license for the using of the Iranian-made “Pastor” vaccine against the coronavirus will be issued next week.
“Also, the licenses for the using of Iranian-made “Razi” and “Fakhra” vaccines will be issued in the near future,” he added.
According to the minister, the Iranian population will be vaccinated fully by the end of autumn with the opportunities created in connection with the production of vaccines in Iran.
Reportedly, about 10 million people in Iran are planned to be vaccinated with the “CovIran Barakat’ vaccine next week. The production of “CovIran Barakat” vaccine in Iran is expected to reach 50 million doses per month by the end of the summer.
On June 14, 26 health and medical facilities were launched in Iran’s Markazi Province. A total of 1.45 trillion rials (about $34.5 million) has been spent on these facilities.
Iran continues to monitor the coronavirus situation in the country. According to recent reports from Iranian officials, over 3.03 million people have been infected, and 82,217 people have already died.
Meanwhile, over 2.66 million people have reportedly recovered from the disease.
The country continues to apply strict measures to contain further spread. Reportedly, the disease was brought to Iran by a businessman from Iran’s Qom city, who went on a business trip to China, despite official warnings. The man died later from the disease.
The Islamic Republic only announced its first infections and deaths from the coronavirus on Feb. 19.
The outbreak in the Chinese city of Wuhan – which is an international transport hub – began at a fish market in late December 2019.
The World Health Organization (WHO) on March 11 declared COVID-19 a pandemic. Some sources claim the coronavirus outbreak started as early as November 2019.
A total of 5.2 million people have been vaccinated in Iran so far. About 4.35 million people were vaccinated on the first stage, and 851,000 people were vaccinated on the second stage.
COVIran Barakat is a COVID-19 vaccine developed by Iranian state-owned Shifa Pharmed Industrial Group. It has successfully been tested on animals and has been approved by the Iran Food and Drug Administration for testing on humans.[1][2][3] Phase 2/3 (II/III) clinical trial began on 13 March 2021,[4] and the first participants were inoculated on March 29.[5] Finally, the vaccine consumption license was issued on June 13, 2021.[6] Around 650 people worked in 3 shifts around the clock to develop the vaccine.[7]
Dr. Minoo Mohraz has been selected as the lead of the “Corona vaccine project in Iran”.[8] Dr. Mohraz is an Iranian physician, scientist, and AIDS specialist. She is a Full Professor (Emeritus) of Infectious Diseases at Tehran University of Medical Sciences and head of the Iranian Centre for HIV/AIDS.[9] Dr. Mohraz has also served as within the World Health Organization as an expert on HIV/AIDS in Iran and the Eastern Mediterranean.[10]
This vaccine has been authorised for emergency use by the Iranian authorities. This makes it the first locally developed to be approved for emergency use in the Middle East.[11]
Technology
On 29 December 2020, human trials of Iran’s first domestic COVID-19 vaccine candidate were started. The mechanism of production of this vaccine is based on the inactivated vaccine. In other words, “it is made of a coronavirus that has been weakened or killed by chemicals, similar to how polio immunizations are made.”[12]
Development

Iran’s first domestic COVID-19 vaccine candidate was started
Tayyebeh Mokhber, the first volunteer who receives a shot of COVIran Barakat was the daughter of Mohammad Mokhber director of setad. Minister of Health Saeed Namaki and Vice President for Science and Technology Sorena Sattari participated at the ceremony of vaccine injection. According to reports, there are more than 65,000 Iranians volunteered to test the vaccine and 56 selected people took part in the first phase of human trials which last 45 to 60 days.[13] The initial phase of human-testing for this vaccine started with the injection of 56 volunteers who were at the age of 18-50.[14][15][16]
The second/third group of volunteers were also injected with the vaccine.[17][18] According to the head of the vaccine production team at the Setad, the results show that this vaccine also neutralizes the British mutated COVID-19 virus.[19][20][21]
In March 2021, the Executive Office of Imam Khomeini’s Order began a Phase II–III clinical trial of COVIran Barakat with 280 participants in cities including Tehran, Mashhad, Karaj, Esfahan, Shiraz. According to the allowance of medical equipment department, the second phase coincided with third phase.[22][23] The vaccine has reached its third phase of human-testing;[24] and the first injection(s) of the 3rd phase began 25 April 2021.[25]
As official in charge of manufacturing Iran Barakat vaccines, Mohammad Reza Salehi said, “some neighboring countries tend to enter the third phase of the clinical trial of the Iranian “COVIran Barakat””. They are reviewing recommendations to let them participate.[14]
Production
According to Setad (the Executive Headquarters of Imam’s Directive), under the direct control of the Supreme Leader of Iran, “production of the vaccine developed by one of its companies, Shifa Pharmed, could reach 12 million doses per month, six months after a successful trial ends”.[26] On 15 March 2021, he stated that EIKO has already a capacity of three million doses per month and that by end of June the capacity will be 15-20 million doses per month.[27][28]
On 29 March 2021, the Tehran Times reported that a capacity of three million doses per month was achieved;[citation needed] and the production line of 25 million doses per month of Iran Koo vaccine was discharged on 26 April 2021.[29]
On 10 May 2021, the first product of mass production of the Iranian corona vaccine called “COVIran Barakat” was unveiled in phase one of the vaccine production factory associated with Execution of Imam Khomeini’s Order (EIKO). Therefore, 2 industrial lines have been set up. The first production line is prepared and the second line is being prepared. By the end of September (taking into account the capacity of three million doses of the first line), 20 million doses of Iran Barakat vaccine will be available in the month.[30]
Authorizations
| Full authorization Emergency authorization |
See also: List of COVID-19 vaccine authorizations § COVIran Barakat
References
- ^ “Iranians demand a COVID-19 vaccine, not politics, from their leaders”. Los Angeles Times. 19 January 2021.
- ^ “Coronavirus Tzar Forced to Apologize to Clergy”. iranwire.
- ^ Vahdat, Amir (29 December 2020). “Iran begins human trials for locally made coronavirus vaccine”. Times of Israel. Retrieved 30 December 2020.
- ^ “IRCT | A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years”. en.irct.ir. Retrieved 2021-04-07.
- ^ 3080 (2021-03-30). “Some foreign states willing to cooperate in COVIran Barakat clinical test: Official”. IRNA English. Retrieved 2021-04-07.
- ^ The vaccine consumption license was issued yjc.ir Retrieved 16 June 2021
- ^ دانش فنی واکسن برکت صد درصد ایرانی است/ تلاش ۶۵۰ نفر در ساخت واکسن ایرانی کرونا
- ^ “Iranian corona vaccine will arrive by ‘next July'”. Persian Bibi (in Persian). 2020-12-06. Retrieved 2020-12-18.
- ^ “Good News About AIDS”. Young Journalists Club. February 6, 2016. Retrieved 2020-02-26.
- ^ “Allameh Tabatabai | Professor Minoo Mehrz: Everything I have is from Tehran University of Medical Sciences”. Tehran University of Medical Sciences Alumni Communication Office. Retrieved March 29, 2017.
- ^ “Iran issues license on its coronavirus vaccine”. Trend.Az. 2021-06-14. Retrieved 2021-06-14.
- ^ “Iran begins first human trial of locally made virus vaccine”. health.economictimes.indiatimes. 29 December 2019.
- ^ “COVIran Barakat: Iran launches human trials of its COVID vaccine”. aljazeera. 29 December 2019.
- ^ Jump up to:a b “Some foreign states willing to cooperate in COVIran Barakat clinical test: Official”. irna.
- ^ Human test of Iranian corona vaccine begins / Minister of Health: We are the first vaccinator in Asia with 100 years of experience tasnimnews.com Retrieved 29 December 2020
- ^ End of the injection of phase one (studies) of “Kovoo-Iran Barakat” vaccineyjc.ir Retrieved 16 February 2021
- ^ Start of injecting the Iranian corona vaccine to the second group of volunteersmehrnews.com
- ^ The injection of “Iranian corona vaccine” to the second group of volunteers began tasnimnews.com
- ^ Jalili: The Iranian vaccine neutralizes the British virus yjc.ir
- ^ Iranian vaccine succeeds in neutralizing “British mutated virus” isna.ir
- ^ “Iran Vaccine Boasts Total Protection Against U.K. Covid Strain”. bloomberg.
- ^ “Clinical trials of COVIRAN vaccine enter phases 2, 3”. isna. 15 March 2021.
- ^ “واکسن ایران برکت احتمالا تا پایان خرداد ۱۴۰۰ به دست هموطنان میرسد”. IRNA. 24 March 2021.
- ^ The beginning of the third stage of the human test of COVIran Barakat IRINN, Retrieved 21 April 2021
- ^ The third phase of Iran Barakat vaccine was injected YJC, Retrieved 25 April 2021
- ^ “Iran starts human testing of first domestic COVID-19 vaccine”. reuters. 29 December 2019.
- ^ “Iran starts mass-production of homegrown coronavirus vaccine”. Tehran Times. 2021-03-15. Retrieved 2021-04-07.
- ^ “Iran to kick off production of 3mn doses of COVIRAN”. Mehr News Agency. 2021-03-15. Retrieved 2021-04-07.
- ^ The production line of 25 million doses per month of Iran Koo vaccine was cleared, Retrieved 4 May 2021
- ^ “نخستین محصول تولید انبوه واکسن “کوو ایران برکت” فردا رونمایی میشود”. irna. 10 May 2021.
External links
| Scholia has a profile for COVIran Barakat (Q105217191). |
/////////COVIran Barakat, iran, coronavirus, COVID-19, vaccine, Shifa Pharmed, SARS-CoV-2

NEW DRUG APPROVALS
one time
$10.00
Share this:
- Click to print (Opens in new window) Print
- Click to share on X (Opens in new window) X
- Click to email a link to a friend (Opens in new window) Email
- Click to share on Pinterest (Opens in new window) Pinterest
- Click to share on LinkedIn (Opens in new window) LinkedIn
- Click to share on Tumblr (Opens in new window) Tumblr
- Click to share on Pocket (Opens in new window) Pocket
- Click to share on Reddit (Opens in new window) Reddit
- Click to share on Facebook (Opens in new window) Facebook










